Niche focus Biotech startup targeting acute and subacute viral diseases with unmet treatment needs, presenting opportunities to align with larger pharma players seeking antiviral candidates and early-stage development partnerships.

Strategic focus areas Initial therapeutic focus on influenza, human rhinovirus, BK virus, and adenovirus suggests potential for collaborations in antiviral drug discovery, preclinical models, and translational research programs with partners specialized in infectious diseases.

Early-stage leverage Small team size and early funding position Via Nova for agile partnerships, CDL (collaboration, discovery, licensing) deals, and joint ventures with established biotechs and CROs to de-risk and accelerate development.

Financial runway With $25M in funding and minimal current revenue, there is an opportunity to present co-development or milestone-based collaboration proposals that align with investor appetite for clinical-stage value creation.

Technical readiness Adoption of modern tech stack (Next.js, JSON-LD, HTTP/3) and digital infrastructure suggests openness to formal collaboration workflows, vendor integrations, and streamlined partner communications to support joint programs.